<DOC>
	<DOCNO>NCT01205178</DOCNO>
	<brief_summary>SB-252263 ( Tafenoquine , TQ ) 8-aminoquinoline ( 8-AQ ) antimalarial drug develop GlaxoSmithKline ( GSK ) , U.S. Army Medical Research Materiel Command ( USAMRMC ) Medicines Malaria Venture ( MMV ) . TQ currently develop radical cure acute P. vivax malaria combination standard dose CQ , 1500 mg 3 day . The current gold standard radical cure P. vivax malaria many area world chloroquine ( CQ ) clearance acute parasitemia immediately follow primaquine ( PQ ) clear liver stage parasite prevent disease relapse . The 8-AQ class drug , include PQ , hemolytic subject glucose-6-phosphate dehydrogenase ( G6PD ) deficiency . The current study identify dose TQ within target efficacious dose range hemolytic effect similar less PQ 15 mg OD x 14 day ( i.e . ≤ 25-30 % hemoglobin decline WHO class III G6PD-deficient subject ) .</brief_summary>
	<brief_title>G6PD ( Glucose-6-phosphate Dehydrogenase ) Study Evaluate Hemolysis Potential TFQ ( Tafenoquine )</brief_title>
	<detailed_description />
	<mesh_term>Malaria</mesh_term>
	<mesh_term>Glucosephosphate Dehydrogenase Deficiency</mesh_term>
	<mesh_term>Primaquine</mesh_term>
	<mesh_term>Chloroquine</mesh_term>
	<mesh_term>Chloroquine diphosphate</mesh_term>
	<mesh_term>Tafenoquine</mesh_term>
	<criteria>A subject eligible inclusion study follow criterion apply : The subject 18 45 year age , inclusive A female eligible enter participate study nonpregnant , nonlactating : Nonchild bear potential define : Is postmenopausal ( 12 month spontaneous amenorrhea 6 month spontaneous amenorrhea serum FSH &gt; 40mIU/mL ) Is premenopausal hysterectomy bilateral oophorectomy ( removal ovary ) bilateral tubal ligation medical report verification . Childbearing potential , negative urine pregnancy test screening , agree comply one follow treatment stage study period 90 day stop study drug : Use oral contraceptive , either combined progestogen alone , combination barrier method ( e.g. , condom diaphragm ) Use intrauterine device document failure rate le 1 % per year Double barrier method consist spermicide either condom diaphragm . Male partner sterile prior female subject 's entry study sole sexual partner female Complete abstinence intercourse 2 week prior administration study drug , throughout study period 90 day stop study drug . A signed date informed consent obtain subject subject 's legal representative prior screen . The subject able understand comply protocol requirement , instruction protocolstated restriction likely complete study plan . WHO class III G6PDdeficiency G6PDnormal status must document enzyme activity cytochemical staining . G6PD genotype must confirm WHO class III G6PD deficiency G6PDnormal status prior TQ dose part study ( i.e. , P. vivax infect subject may commence CQ therapy whilst cytochemical staining , enzyme activity G6PD genotype determine ) . Supplemental Inclusion Criteria Part A : Healthy volunteer Inclusion criterion 17 AND Subject female For G6PDdeficient subject ( WHO class III variant ) , subject must heterozygous 4060 % normal RBCs cytochemical staining method . For G6PDnormal subject , subject must &gt; 90 % normal RBCs cytochemical staining method . Supplemental Inclusion Criteria Part B : P. vivax patient Inclusion criterion 17 AND Subject female Positive blood smear P. vivax parasite density &gt; 500 &lt; 200,000/µl For G6PDdeficient subject ( WHO class III variant ) , subject must heterozygous 4060 % normal RBC cytochemical staining method . For G6PDnormal subject , subject must &gt; 90 % normal RBCs cytochemical staining method . Supplemental Inclusion Criteria Part C : P. vivax patient Inclusion criterion 17 AND Positive blood smear P. vivax parasite density &gt; 500 &lt; 200,000/µl For G6PDdeficient subject ( WHO class III variant ) , subject homozygous female hemizygous male . For G6PDnormal subject , subject must &gt; 90 % normal RBCs cytochemical staining method A subject eligible inclusion study follow criterion apply : Clinically significant illness ( intercurrent illness e.g . pneumonia , preexist condition e.g . renal disease , malignancy condition may affect absorption study medication e.g . severe diarrhea sign malnutrition define clinically , clinical sign symptom vascular disease ( e.g . cardiac , CNS , diabetes , hyperlipidemia , etc. ) . Any clinically relevant biological physical abnormality find report screening , opinion investigator , clinically significant would preclude safe participation study . These abnormality may identify screen history physical laboratory examination , 12lead electrocardiogram ( ECG ) . Mixed malaria infection Giemsa smear . Female subject pregnant , lactate unwilling/unable comply recognize contraceptive method treatment stage study period 90 day stop study drug . Symptoms severe vomiting ( food inability take food previous 8 hour ) . History hemoglobinopathy ( e.g . sicklecell disease , hereditary spherocytosis , thalassemia , hemoglobin M , etc . ) ; current past history methemoglobinemia methemoglobin percentage 3 % . History porphyria History psoriasis History allergy tafenoquine , chloroquine , primaquine , mefloquine 4 8aminoquinolines . Subject take antimalarial ( e.g. , mefloquine , primaquine , chloroquine ) within past 60 day history . Treatment investigational drug within 30 day 5 halflives ( whichever longer ) precede first dose study medication . Donation blood excess 500mL within 56 day prior dose study drug . History regular alcohol consumption exceed 7 drinks/week woman 14 drinks/week men ( one drink = five ounce wine 12 ounce beer 1.5 ounce hard liquor ) within 6 month screen . History illicit drug abuse within 6 month study . Heparin sensitivity ( heparin use maintain intravenous catheter patency ) . QTc interval &gt; 450 msec screen Supplemental Exclusion Criteria Part A : Healthy volunteer Exclusion criterion 116 AND Baseline Hgb &lt; 12 g/dL ( Hct &lt; 36 % ) . Value verify conduct two measurement ( single blood draw ) . Use prescription nonprescription drug , vitamin , herbal dietary supplement within 7 day 5 halflives ( whichever longer ) prior first dose study medication , use St. John 's Wort within 28 day prior first dose study medication . Unless opinion investigator sponsor medication interfere study procedure compromise safety . By exception , subject may take paracetamol acetaminophen ( ≤2 grams/day ) 48 hour prior first dose study medication . Supplemental Exclusion Criteria Parts B C : P. vivax patient Exclusion criterion 116 AND Laboratory criterion exclusion : platelet &lt; 50,000/µL WBC &lt; 2000/µL Calculated creatinine clearance ( CrCl ) &lt; 50ml/min CockcroftGault formula : Men : CrCl = ( 140 age ) x weight ( kg ) / ( 72 x SCr* ) Woman : CrCl = [ ( 140 age ) x weight ( kg ) / ( 72 x SCr* ) ] x 0.85 *SCr= serum creatinine ALT AST &gt; 2 time upper limit reference range Total bilirubin level &gt; 1.5 time upper limit reference range screening . Screening Hgb &lt; 11 g/dL ( Hct &lt; 33 % ) . Value verify conduct two measurement ( single blood draw ) . Subjects take likely require use medication prohibit medication list include follow class : Histamine2 blocker antacids Drugs hemolytic potential Drugs know prolong QTc interval</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>45 Years</maximum_age>
	<verification_date>November 2013</verification_date>
</DOC>